Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

OBJECTIVE: Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NF‐kB suppressor, targets dysfunctional inflammatory, metabolic, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, David R., Farmer, Jennifer, Hauser, Lauren, Blair, Ian A., Wang, Qing Qing, Mesaros, Clementina, Snyder, Nathaniel, Boesch, Sylvia, Chin, Melanie, Delatycki, Martin B., Giunti, Paola, Goldsberry, Angela, Hoyle, Chad, McBride, Michael G., Nachbauer, Wolfgang, O'Grady, Megan, Perlman, Susan, Subramony, S. H., Wilmot, George R., Zesiewicz, Theresa, Meyer, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331199/
https://www.ncbi.nlm.nih.gov/pubmed/30656180
http://dx.doi.org/10.1002/acn3.660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331199/
https://www.ncbi.nlm.nih.gov/pubmed/30656180
http://dx.doi.org/10.1002/acn3.660

Ejemplares similares